Compare MSBI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | IPSC |
|---|---|---|
| Founded | 1881 | 2019 |
| Country | United States | United States |
| Employees | 861 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.1M | 413.0M |
| IPO Year | N/A | 2021 |
| Metric | MSBI | IPSC |
|---|---|---|
| Price | $27.69 | $2.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $4.25 |
| AVG Volume (30 Days) | 133.7K | ★ 644.7K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $14.24 | $0.44 |
| 52 Week High | $28.53 | $2.97 |
| Indicator | MSBI | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 49.15 |
| Support Level | $26.20 | $2.15 |
| Resistance Level | $28.53 | $2.41 |
| Average True Range (ATR) | 0.71 | 0.13 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 65.78 | 56.67 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.